Aktis Oncology AKTS
$16.15 −$0.25 (-1.52%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $16.46 +1.92%
Open$16.32
Prev close$16.40
Day range$16.00 – $16.74
Volume375.0K
Market cap$901.14M
P/E (TTM)–
Dividend yield–
AKTS Stock News
Headlines matching Aktis Oncology or the AKTS ticker, most recent first.
- Oppenheimer Initiates Aktis Oncology(AKTS.US) With Buy Rating, Announces Target Price $40
- Wedbush Initiates Aktis Oncology(AKTS.US) With Buy Rating, Announces Target Price $35
- J.P. Morgan Maintains Aktis Oncology(AKTS.US) With Buy Rating, Maintains Target Price $33
- Analysts Have Conflicting Sentiments on These NA Companies: Aktis Oncology, Inc. (AKTS), Bullish (BLSH) and SanDisk Corp (SNDK) Positive
- William Blair Maintains Aktis Oncology(AKTS.US) With Buy Rating
- Aktis Oncology, Inc. (AKTS) Receives a Buy From Bank of America Securities
- Analysts Are Bullish on Top NA Stocks: Aktis Oncology, Inc. (AKTS), Yesway Inc Class A (YSWY) Positive
- BofA Securities Maintains Aktis Oncology(AKTS.US) With Buy Rating, Maintains Target Price $34
- J.P. Morgan Maintains Aktis Oncology(AKTS.US) With Buy Rating, Raises Target Price to $33 Positive
- J.P. Morgan Keeps Their Buy Rating on Aktis Oncology, Inc. (AKTS)
- H.C. Wainwright Maintains Aktis Oncology(AKTS.US) With Buy Rating, Maintains Target Price $35
- H.C. Wainwright Maintains Aktis Oncology(AKTS.US) With Buy Rating, Raises Target Price to $35 Positive
- Raymond James Maintains Aktis Oncology(AKTS.US) With Buy Rating, Maintains Target Price $40
- Bank of America Securities Remains a Buy on Aktis Oncology, Inc. (AKTS)
- William Blair Initiates Aktis Oncology(AKTS.US) With Buy Rating
No comments yet — be the first to weigh in on AKTS.
Sign in to join the discussion.